Lovotibeglogene autotemcel

罗沃基奥干赛

Report date: 2026/03/09 20:02:04

Base Information

Drug NameLovotibeglogene autotemcel
Drug Alias NameLentiviral beta AT87Q-Globin vectorLentiviral β-A(T87Q)-Globin VectorSickle cell anaemia gene therapyAutologous CD34+ cells encoding βA-T87Q-globin geneLentiGlobin BB305 Drug Product for SCD +[17] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionGene transferenceHemoglobin beta chain stimulants
TargetsHemoglobin beta chain
Therapy Area/IndicationsAnemia, Sickle Cell
Global Approved IndicationsAnemia, Sickle Cell
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/12/08
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGenetix Biotherapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenetix Biotherapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnemia, Sickle Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank